Drugs / Omeprazol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04504045 | Sep 2020 → May 2022 | type 2 diabetes mellitus | University of Southern Denmark | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01585623 | Jun 2012 → Mar 2013 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT05134584 Background | Jan → Dec 2021 | dyspepsia, irritable bowel syndrome | RenJi Hospital | Unknown | Met primary |
| — | NCT05256342 Comparator | Dec 2021 → Apr 2024 | osteoarthritis, knee | Rambam Health Care Campus | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | omeprazol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01585623 ↗ |
| Route | Oral | “Route of administration: oral” NCT01585623 ↗ |